Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumor G2”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Looking for participantsNCT05773274
What this trial is testing

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Who this might be right for
Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI) 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT01841736
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Who this might be right for
Foregut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1+5 more
National Cancer Institute (NCI) 171
Large-scale testing (Phase 3)Active Not RecruitingNCT03375320
What this trial is testing

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Who this might be right for
Functioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Neoplasm+25 more
National Cancer Institute (NCI) 298
Post-approval studies (Phase 4)Looking for participantsNCT06016855
What this trial is testing

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more
Vanderbilt-Ingram Cancer Center 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Large-scale testing (Phase 3)UnknownNCT01744249
What this trial is testing

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Who this might be right for
Neuroendocrine TumorsAdvanced Cancer
Grupo Espanol de Tumores Neuroendocrinos 255
Not applicableStudy completedNCT03667092
What this trial is testing

Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor

Who this might be right for
Midgut Neuroendocrine Tumors
University Hospital, Toulouse 47
Not applicableStudy completedNCT06080204
What this trial is testing

Real-world Study on Adjuvant Octreotide Therapy in pNETs

Who this might be right for
Pancreatic Neuroendocrine Tumor G2
Changhai Hospital 411
Testing effectiveness (Phase 2)Looking for participantsNCT04665739
What this trial is testing

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Who this might be right for
Advanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT02893930
What this trial is testing

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Who this might be right for
Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma
National Cancer Institute (NCI) 13
Early research (Phase 1)Not Yet RecruitingNCT07150546
What this trial is testing

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Who this might be right for
Digestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more
Emory University 15
Not applicableActive Not RecruitingNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Advanced Accelerator Applications 164
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Testing effectiveness (Phase 2)Study completedNCT01229943
What this trial is testing

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more
National Cancer Institute (NCI) 150
Not applicableActive Not RecruitingNCT04804371
What this trial is testing

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 40
Large-scale testing (Phase 3)Active Not RecruitingNCT00569127
What this trial is testing

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Who this might be right for
Colorectal Neuroendocrine Tumor G1Gastric Neuroendocrine Tumor G1Neuroendocrine Neoplasm+2 more
National Cancer Institute (NCI) 427